This course has expired. View available courses.
Oncology, Screening & Prevention, Women's Health
Better outcomes for patients with HR+/HER2- breast cancer: spotlight on CDK4/6 inhibitors
This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.
This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
1
ACCREDITATION
RACP
EXPIRY DATE
2023-06-08
This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.
This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.
Faculty
Dr Shom Goel, B Med Sci (Hons), MBBS (Hons), FRACP, PhD
(Melbourne, VIC)
Dr Elgene Lim, MBBS FRACP PhD
(Sydney, NSW)
Dr Otto Metzger, M.D.
(Boston, MA)
Learning objectives
On completion of this program, participants will be better able to:
- Outline efficacy data for CDK4/6 inhibitors as first- and second-line therapy for advanced hormone receptor-positive breast cancer
- Identify when is it appropriate to use a CDK4/6 inhibitor as first-line therapy for advanced hormone receptor-positive breast cancer
- Describe the adverse effects of the available CDK4/6 inhibitors, how they differ and what the guidelines recommend regarding monitoring and management of toxicity
- Recognise baseline risk of adverse effects and potential drug-drug interactions
Accreditation
#
of credits: 1
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Specialist
Profession
1
# of credits
Learning Objectives
On completion of this program, participants will be better able to:
- Outline efficacy data for CDK4/6 inhibitors as first- and second-line therapy for advanced hormone receptor-positive breast cancer
- Identify when is it appropriate to use a CDK4/6 inhibitor as first-line therapy for advanced hormone receptor-positive breast cancer
- Describe the adverse effects of the available CDK4/6 inhibitors, how they differ and what the guidelines recommend regarding monitoring and management of toxicity
- Recognise baseline risk of adverse effects and potential drug-drug interactions
RACP
ACCREDITATION
Oncology, Screening & Prevention, Women's Health
Learning Category
Medication
Topic
0
Price
2023-06-08
Expiry Date
AUS
Region/Language
Course Description
This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.
This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.
Faculty
Dr Shom Goel, B Med Sci (Hons), MBBS (Hons), FRACP, PhD
(Melbourne, VIC)
Dr Elgene Lim, MBBS FRACP PhD
(Sydney, NSW)
Dr Otto Metzger, M.D.
(Boston, MA)
Accreditation
This interactive online learning activity is valued at 1 Hour of continuing education with RACP.
1 hr
Duration
0
Price
1
# of credits
